AbstractTo better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined associations between viral genetic diversity and the NAb response against a multi-subtype panel of heterologous viruses in a well-characterized, therapy-naïve primary infection cohort. Using next generation sequencing (NGS), we computed sequence-based measures of diversity within HIV-1 env, gag and pol, and compared them to NAb breadth and potency as calculated by a neutralization score. Contemporaneous env diversity and the neutralization score were positively correlated (p=0.0033), as were the neutralization score and estimated duration of infection (EDI) (p=0.0038), and env diversity and EDI (p=0.0005). Neither early env diversity nor basel...
A goal of HIV vaccine development is to elicit antibodies with neutralizing breadth. Broadly neutral...
Investigating the incidence and prevalence of HIV-1 superinfection is challenging due to the complex...
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-i...
To better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined associati...
AbstractTo better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined a...
Although antiretroviral therapy (ART) successfully suppresses HIV-1 replication, ART-treated individ...
AbstractWide differences exist among primary isolates of HIV-1 in their sensitivity to antibody-medi...
Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the acquisition ...
Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the acquisition ...
Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course of infection...
Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course of infection...
AbstractWide differences exist among primary isolates of HIV-1 in their sensitivity to antibody-medi...
BACKGROUND Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course ...
BACKGROUND Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course ...
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-i...
A goal of HIV vaccine development is to elicit antibodies with neutralizing breadth. Broadly neutral...
Investigating the incidence and prevalence of HIV-1 superinfection is challenging due to the complex...
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-i...
To better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined associati...
AbstractTo better understand the dynamics of HIV-specific neutralizing antibody (NAb), we examined a...
Although antiretroviral therapy (ART) successfully suppresses HIV-1 replication, ART-treated individ...
AbstractWide differences exist among primary isolates of HIV-1 in their sensitivity to antibody-medi...
Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the acquisition ...
Neutralizing antibodies (nAbs) are a high priority for vaccines that aim to prevent the acquisition ...
Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course of infection...
Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course of infection...
AbstractWide differences exist among primary isolates of HIV-1 in their sensitivity to antibody-medi...
BACKGROUND Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course ...
BACKGROUND Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course ...
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-i...
A goal of HIV vaccine development is to elicit antibodies with neutralizing breadth. Broadly neutral...
Investigating the incidence and prevalence of HIV-1 superinfection is challenging due to the complex...
Strain-specific neutralizing antibodies develop in all human immunodeficiency virus type 1 (HIV-1)-i...